|
|
CBD FOR ACNE
|
Cannabidiol as a Treatment for Acne?
|
|
CBD FOR ACNE
|
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
|
|
CBD FOR ACNE
|
The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities
|
|
CBD FOR ACNE
|
Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling
|
|
CBD FOR ACNE
|
Endocannabinoid signaling and epidermal differentiation
|
|
6
|
CBD FOR ADD / ADHD
|
Searching for a Neurobiological Basis for Self-Medication Theory in ADHD Comorbid With Substance Use Disorders
|
|
CBD FOR ADD / ADHD
|
Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats
|
|
CBD FOR ADD / ADHD
|
Subtypes of Attention Deficit — Hyperactivity Disorder (ADHD) and cannabis use
|
|
CBD FOR ADD / ADHD
|
Childhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students
|
|
CBD FOR ADD / ADHD
|
Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report
|
|
CBD FOR ADD / ADHD
|
Fitness to drive in spite (because) of THC
|
|
10
|
CBD FOR ADDICTION
|
Cannabidiol reduces cigarette consumption in tobacco smokers
|
|
CBD FOR ADDICTION
|
Cannabidiol inhibits the reward-facilitating effect of morphine
|
|
CBD FOR ADDICTION
|
Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances
|
|
CBD FOR ADDICTION
|
Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats
|
|
CBD FOR ADDICTION
|
Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment
|
|
CBD FOR ADDICTION
|
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010
|
|
CBD FOR ADDICTION
|
Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents
|
|
CBD FOR ADDICTION
|
Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity
|
|
CBD FOR ADDICTION
|
Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder
|
|
CBD FOR ADDICTION
|
Cannabidiol for the treatment of cannabis withdrawal syndrome
|
|
4
|
CBD FOR ALS
|
Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials
|
|
CBD FOR ALS
|
ALS: delayed disease progression in mice by treatment with a cannabinoid
|
|
CBD FOR ALS
|
The (Endo)Cannabinoid System in Multiple Sclerosis and ALS
|
|
CBD FOR ALS
|
Survey of cannabis use in patients with ALS
|
|
16
|
CBD FOR ALZHEIMERS
|
The therapeutic potential of the endocannabinoid system for Alzheimer’s disease
|
|
CBD FOR ALZHEIMERS
|
Endocannabinoid signalling in Alzheimer’s disease
|
|
CBD FOR ALZHEIMERS
|
A molecular link between the active component of marijuana and Alzheimer’s disease pathology
|
|
CBD FOR ALZHEIMERS
|
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
|
|
CBD FOR ALZHEIMERS
|
The Potential Therapeutic Effects of THC on Alzheimer’s Disease
|
|
CBD FOR ALZHEIMERS
|
The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease
|
|
CBD FOR ALZHEIMERS
|
Cannabinoids for the treatment of dementia
|
|
CBD FOR ALZHEIMERS
|
Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression
|
|
CBD FOR ALZHEIMERS
|
Cannabidiol: A promising drug for neurodegenerative disorders?
|
|
CBD FOR ALZHEIMERS
|
Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
|
|
CBD FOR ALZHEIMERS
|
The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses
|
|
CBD FOR ALZHEIMERS
|
The role of phytochemicals in the treatment and prevention of dementia
|
|
CBD FOR ALZHEIMERS
|
Cannabinoids for the treatment of dementia
|
|
CBD FOR ALZHEIMERS
|
Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement
|
|
CBD FOR ALZHEIMERS
|
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
|
|
CBD FOR ALZHEIMERS
|
Can Marijuana Prevent Alzheimer’s?
|
|
4
|
CBD FOR ANOREXIA
|
Leptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa
|
|
CBD FOR ANOREXIA
|
The role of the endocannabinoid system in eating disorders: Neurochemical and behavioural preclinical evidence
|
|
CBD FOR ANOREXIA
|
Cancer cachexia and cannabinoids
|
|
CBD FOR ANOREXIA
|
Brain Type 1 Cannabinoid Receptor Availability in Patients with Anorexia and Bulimia Nervosa
|
|
9
|
CBD FOR ANXIETY
|
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
|
|
CBD FOR ANXIETY
|
Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa
|
|
CBD FOR ANXIETY
|
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients
|
|
CBD FOR ANXIETY
|
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder
|
|
CBD FOR ANXIETY
|
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation
|
|
CBD FOR ANXIETY
|
Effects of cannabidiol (CBD) on regional cerebral blood flow
|
|
CBD FOR ANXIETY
|
The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
|
|
CBD FOR ANXIETY
|
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
|
|
CBD FOR ANXIETY
|
Plant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence
|
|
4
|
CBD FOR ATHEROSCLEROSIS
|
The role of the endocannabinoid system in atherosclerosis
|
|
CBD FOR ATHEROSCLEROSIS
|
Cannabinoid receptors in atherosclerosis
|
|
CBD FOR ATHEROSCLEROSIS
|
The potential use of cannabidiol in the therapy of metabolic syndrome
|
|
CBD FOR ATHEROSCLEROSIS
|
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
|
|
4
|
CBD FOR ARTHRITIS
|
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
|
|
CBD FOR ARTHRITIS
|
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
|
|
CBD FOR ARTHRITIS
|
The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55
|
|
CBD FOR ARTHRITIS
|
Arthritis and cannabinoids
|
|
5
|
CBD FOR ASTHMA
|
The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke
|
|
CBD FOR ASTHMA
|
Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma
|
|
CBD FOR ASTHMA
|
Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs
|
|
CBD FOR ASTHMA
|
Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways
|
|
CBD FOR ASTHMA
|
Bronchodilator effect of delta1-tetrahydrocannabinol
|
|
5
|
CBD FOR AUTISM
|
Mutations found in individuals with autism interfere with endocannabinoid signaling in the brain
|
|
CBD FOR AUTISM
|
Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders
|
|
CBD FOR AUTISM
|
A novel approach to the symptomatic treatment of autism
|
|
CBD FOR AUTISM
|
Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders
|
|
CBD FOR AUTISM
|
Targeting the endocannabinoid system in the treatment of fragile X syndrome
|
|
5
|
CBD FOR BIPOLAR AFFECTIVE DISORDER
|
Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential
|
|
CBD FOR BIPOLAR AFFECTIVE DISORDER
|
Cannabidiol was ineffective for manic episode of bipolar affective disorder
|
|
CBD FOR BIPOLAR AFFECTIVE DISORDER
|
Effects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania
|
|
CBD FOR BIPOLAR AFFECTIVE DISORDER
|
Does Cannabis Use Affect Treatment Outcome in Bipolar Disorder?: A Longitudinal Analysis
|
|
CBD FOR BIPOLAR AFFECTIVE DISORDER
|
The Use of Cannabis as a Mood Stabilizer in Bipolar Disorder: Anecdotal Evidence and the Need for Clinical Research
|
|
5
|
CBD FOR CANCER - GENERAL
|
Cannabidiol as potential anticancer drug
|
|
CBD FOR CANCER - GENERAL
|
Cannabidiol inhibits angiogenesis by multiple mechanisms
|
|
CBD FOR CANCER - GENERAL
|
The inhibitory effects of cannabidiol on systemic malignant tumors
|
|
CBD FOR CANCER - GENERAL
|
Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1
|
|
CBD FOR CANCER - GENERAL
|
Marijuana fights cancer and helps manage side effects
|
|
4
|
CBD FOR CANCER - LUNG
|
Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1C
|
|
CBD FOR CANCER - LUNG
|
COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells
|
|
CBD FOR CANCER - LUNG
|
Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells
|
|
CBD FOR CANCER - LUNG
|
Media ignored expert’s shocking findings that marijuana helps prevent lung cancer
|
|
5
|
CBD FOR CANCER - PROSTATE/COLON
|
Towards the use of non-psychoactive cannabinoids for prostate cancer
|
|
CBD FOR CANCER - PROSTATE/COLON
|
In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines
|
|
CBD FOR CANCER - PROSTATE/COLON
|
Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent
|
|
CBD FOR CANCER - PROSTATE/COLON
|
Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer
|
|
CBD FOR CANCER - PROSTATE/COLON
|
Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol
|
|
5
|
CBD FOR CANCER - BREAST
|
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma
|
|
CBD FOR CANCER - BREAST
|
Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy
|
|
CBD FOR CANCER - BREAST
|
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
|
|
CBD FOR CANCER - BREAST
|
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
|
|
CBD FOR CANCER - BREAST
|
Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration
|
|
8
|
CBD FOR CANCER - BRAIN
|
Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival
|
|
CBD FOR CANCER - BRAIN
|
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines(PubMed)
|
|
CBD FOR CANCER - BRAIN
|
Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas
|
|
CBD FOR CANCER - BRAIN
|
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism
|
|
CBD FOR CANCER - BRAIN
|
Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target
|
|
CBD FOR CANCER - BRAIN
|
Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
|
|
CBD FOR CANCER - BRAIN
|
Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect
|
|
CBD FOR CANCER - BRAIN
|
Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme
|
|
4
|
CBD FOR CANCER - LEUKEMIA
|
Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression
|
|
CBD FOR CANCER - LEUKEMIA
|
Cannabidiol-Induced Apoptosis in Human Leukemia Cells
|
|
CBD FOR CANCER - LEUKEMIA
|
Cannabidiol Reduces Leukemic Cell Size – But Is It Important?
|
|
CBD FOR CANCER - LEUKEMIA
|
Targeting cannabinoid receptors to treat leukemia
|
|
4
|
CBD FOR CANCER - SKIN
|
Anticancer activity of anandamide in human cutaneous melanoma cells
|
|
CBD FOR CANCER - SKIN
|
Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium (PubMed)
|
|
CBD FOR CANCER - SKIN
|
Cannabinoid receptors as novel targets for the treatment of melanoma
|
|
CBD FOR CANCER - SKIN
|
The Cannabinoid Receptors Are Required for Ultraviolet-Induced Inflammation and Skin Cancer Development
|
|
4
|
CBD FOR CANCER - ENDOCRINE
|
Endocannabinoids in endocrine and related tumours
|
|
CBD FOR CANCER - ENDOCRINE
|
A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells
|
|
CBD FOR CANCER - ENDOCRINE
|
Cannabinoids in pancreatic cancer: Correlation with survival and pain
|
|
CBD FOR CANCER - ENDOCRINE
|
Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma
|
|
4
|
CBD FOR CANCER - BLADDER
|
TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer
|
|
CBD FOR CANCER - BLADDER
|
Association Between Cannabis Use and the Risk of Bladder Cancer
|
|
CBD FOR CANCER - BLADDER
|
Inhibitory Effect of Standardized Cannabis sativaExtract and Its Ingredient Cannabidiol on Rat and Human Bladder Contractility
|
|
CBD FOR CANCER - BLADDER
|
Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism
|
|
4
|
CBD FOR CANCER - PAIN RELIEF
|
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
|
|
CBD FOR CANCER - PAIN RELIEF
|
Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
|
|
CBD FOR CANCER - PAIN RELIEF
|
Marijuana extract helps prevent chemo pain
|
|
CBD FOR CANCER - PAIN RELIEF
|
An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics
|
|
10
|
CBD FOR CROHNS & COLITIS
|
Cannabidiol in inflammatory bowel diseases: a brief overview
|
|
CBD FOR CROHNS & COLITIS
|
Cannabis finds its way into treatment of Crohn’s disease
|
|
CBD FOR CROHNS & COLITIS
|
Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis
|
|
CBD FOR CROHNS & COLITIS
|
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
|
|
CBD FOR CROHNS & COLITIS
|
The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
|
|
CBD FOR CROHNS & COLITIS
|
Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
|
|
CBD FOR CROHNS & COLITIS
|
Cannabinoids and the gut: New developments and emerging concepts
|
|
CBD FOR CROHNS & COLITIS
|
Endocannabinoids and the gastrointestinal tract
|
|
CBD FOR CROHNS & COLITIS
|
Cannabinoids and gastrointestinal motility: Animal and human studies
|
|
CBD FOR CROHNS & COLITIS
|
Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
|
|
11
|
CBD FOR DEPRESSION
|
Endocannabinoid system dysfunction in mood and related disorders
|
|
CBD FOR DEPRESSION
|
Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa
|
|
CBD FOR DEPRESSION
|
The endocannabinoid system and the treatment of mood and anxiety disorders
|
|
CBD FOR DEPRESSION
|
Endocannabinoid signaling in the etiology and treatment of major depressive illness
|
|
CBD FOR DEPRESSION
|
Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors
|
|
CBD FOR DEPRESSION
|
Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants
|
|
CBD FOR DEPRESSION
|
Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa
|
|
CBD FOR DEPRESSION
|
Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress
|
|
CBD FOR DEPRESSION
|
Serum contents of endocannabinoids are correlated with blood pressure in depressed women
|
|
CBD FOR DEPRESSION
|
The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants
|
|
CBD FOR DEPRESSION
|
Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures
|
|
21
|
CBD FOR ENDOCRINE DISORDERS
|
Endocannabinoid system participates in neuroendocrine control of homeostasis
|
|
CBD FOR ENDOCRINE DISORDERS
|
The emerging role of the endocannabinoid system in endocrine regulation and energy balance
|
|
CBD FOR ENDOCRINE DISORDERS
|
Endocannabinoids in endocrine and related tumours
|
|
CBD FOR ENDOCRINE DISORDERS
|
Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas
|
|
CBD FOR ENDOCRINE DISORDERS
|
The role of the endocannabinoid system in the neuroendocrine regulation of energy balance
|
|
CBD FOR ENDOCRINE DISORDERS
|
CBD for children with Dravet’s and intractable seizures
|
|
CBD FOR ENDOCRINE DISORDERS
|
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
|
|
CBD FOR ENDOCRINE DISORDERS
|
Medicinal marijuana stops seizures, brings hope to a little girl
|
|
CBD FOR ENDOCRINE DISORDERS
|
Cannabinoids for epilepsy
|
|
CBD FOR ENDOCRINE DISORDERS
|
Cannabis, cannabidiol, and epilepsy – From receptors to clinical response
|
|
CBD FOR ENDOCRINE DISORDERS
|
The non-psychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability
|
|
CBD FOR ENDOCRINE DISORDERS
|
Chronic administration of cannabidiol to healthy volunteers and epileptic patients
|
|
CBD FOR ENDOCRINE DISORDERS
|
Endocannabinoid system protects against cryptogenic seizures
|
|
CBD FOR ENDOCRINE DISORDERS
|
Seizing an opportunity for the endocannabinoid system
|
|
CBD FOR ENDOCRINE DISORDERS
|
Cannabidiol: promise and pitfalls
|
|
CBD FOR ENDOCRINE DISORDERS
|
Cannabidivarin (CBDV) suppressespentylenetetrazole (PTZ)-inducedincreases in epilepsy-related gene expression
|
|
CBD FOR ENDOCRINE DISORDERS
|
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
|
|
CBD FOR ENDOCRINE DISORDERS
|
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo
|
|
CBD FOR ENDOCRINE DISORDERS
|
Hypnotic and antiepileptic effects of cannabidiol
|
|
CBD FOR ENDOCRINE DISORDERS
|
The cannabinoids as potential antiepileptics
|
|
CBD FOR ENDOCRINE DISORDERS
|
Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats
|
|
5
|
CBD FOR FIBROMYALGIA
|
Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
|
|
CBD FOR FIBROMYALGIA
|
Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life
|
|
CBD FOR FIBROMYALGIA
|
Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia
|
|
CBD FOR FIBROMYALGIA
|
Cannabinoids for fibromyalgia
|
|
CBD FOR FIBROMYALGIA
|
Medical Cannabis for the Treatment of Fibromyalgia
|
|
4
|
CBD FOR GLAUCOMA
|
Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite
|
|
CBD FOR GLAUCOMA
|
Cannabinoids and glaucoma
|
|
CBD FOR GLAUCOMA
|
The treatment of glaucoma using a non-psychoactive preparation of Cannabis sativa
|
|
CBD FOR GLAUCOMA
|
Cannabinoids for treatment of glaucoma
|
|
7
|
CBD FOR HEART DISEASE
|
Is the cardiovascular system a therapeutic target for cannabidiol?
|
|
CBD FOR HEART DISEASE
|
Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion
|
|
CBD FOR HEART DISEASE
|
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy
|
|
CBD FOR HEART DISEASE
|
The Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias: The Role of Adenosine A1 Receptors
|
|
CBD FOR HEART DISEASE
|
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
|
|
CBD FOR HEART DISEASE
|
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension
|
|
CBD FOR HEART DISEASE
|
Oleamide: A fatty acid amide signaling molecule in the cardiovascular system?
|
|
6
|
CBD FOR HUNTINGTONS DISEASE
|
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease
|
|
CBD FOR HUNTINGTONS DISEASE
|
Cannabinoids: Novel medicines for the treatment of Huntington’s disease
|
|
CBD FOR HUNTINGTONS DISEASE
|
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB(1) and CB(2) receptors
|
|
CBD FOR HUNTINGTONS DISEASE
|
Controlled clinical trial of cannabidiol in Huntington’s disease
|
|
CBD FOR HUNTINGTONS DISEASE
|
Prospects for cannabinoid therapies in basal ganglia disorders
|
|
CBD FOR HUNTINGTONS DISEASE
|
Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
|
|
13
|
CBD FOR INFLAMMATION
|
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
|
|
CBD FOR INFLAMMATION
|
The endocannabinoid system: an emerging key player in inflammation
|
|
CBD FOR INFLAMMATION
|
Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice
|
|
CBD FOR INFLAMMATION
|
Cannabinoids, endocannabinoids, and related analogs in inflammation
|
|
CBD FOR INFLAMMATION
|
Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor
|
|
CBD FOR INFLAMMATION
|
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
|
|
CBD FOR INFLAMMATION
|
Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis
|
|
CBD FOR INFLAMMATION
|
Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation
|
|
CBD FOR INFLAMMATION
|
Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement
|
|
CBD FOR INFLAMMATION
|
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption
|
|
CBD FOR INFLAMMATION
|
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
|
|
CBD FOR INFLAMMATION
|
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death
|
|
CBD FOR INFLAMMATION
|
Cannabinoids in clinical practice
|
|
9
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Cannabidiol in inflammatory bowel diseases: A brief overview
|
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis
|
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
|
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
|
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Therapeutic potential of cannabinoid-based drugs
|
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)
|
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Cannabinoids and the gut: New developments and emerging concepts
|
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Endocannabinoids and the gastrointestinal tract
|
|
CBD FOR IRRITABLE BOWEL SYNDROME
|
Cannabinoids and gastrointestinal motility: Animal and human studies
|
|
4
|
CBD FOR KIDNEY DISEASE
|
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death
|
|
CBD FOR KIDNEY DISEASE
|
Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay
|
|
CBD FOR KIDNEY DISEASE
|
Is There a Legitimate Role for the Therapeutic Use of Cannabinoids for Symptom Management in Chronic Kidney Disease?
|
|
CBD FOR KIDNEY DISEASE
|
The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases
|
|
7
|
CBD FOR LIVER DISEASE
|
The endocannabinoid system and liver diseases
|
|
CBD FOR LIVER DISEASE
|
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death
|
|
CBD FOR LIVER DISEASE
|
Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis
|
|
CBD FOR LIVER DISEASE
|
Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats
|
|
CBD FOR LIVER DISEASE
|
Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol
|
|
CBD FOR LIVER DISEASE
|
Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice
|
|
CBD FOR LIVER DISEASE
|
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation
|
|
5
|
CBD FOR METABOLIC SYNDROME
|
The impact of marijuana use on glucose, insulin, and insulin resistance among US adults
|
|
CBD FOR METABOLIC SYNDROME
|
The potential use of cannabidiol in the therapy of metabolic syndrome
|
|
CBD FOR METABOLIC SYNDROME
|
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes
|
|
CBD FOR METABOLIC SYNDROME
|
Metabolic syndrome in people with a psychotic illness: is cannabis protective?
|
|
CBD FOR METABOLIC SYNDROME
|
Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome
|
|
5
|
CBD FOR MIGRAINES
|
Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
|
|
CBD FOR MIGRAINES
|
Effects of anandamide in migraine: data from an animal model
|
|
CBD FOR MIGRAINES
|
Cannabinoids and hallucinogens for headache
|
|
CBD FOR MIGRAINES
|
The endocannabinoid system and migraine
|
|
CBD FOR MIGRAINES
|
Variations in the cannabinoid receptor 1 gene predispose to migraine
|
|
6
|
CBD FOR MOOD DISORDERS
|
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
|
|
CBD FOR MOOD DISORDERS
|
The endocannabinoid system and the treatment of mood and anxiety disorders
|
|
CBD FOR MOOD DISORDERS
|
The endocannabinoid system and psychiatric disorders
|
|
CBD FOR MOOD DISORDERS
|
The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives
|
|
CBD FOR MOOD DISORDERS
|
Endocannabinoid system dysfunction in mood and related disorders
|
|
CBD FOR MOOD DISORDERS
|
Effects of cannabidiol (CBD) on regional cerebral blood flow
|
|
3
|
CBD FOR MOTION SICKNESS
|
Motion sickness, stress and the endocannabinoid system
|
|
CBD FOR MOTION SICKNESS
|
Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system
|
|
CBD FOR MOTION SICKNESS
|
The Effects of Cannabidiol and Tetrahydrocannabinol on Motion‐Induced Emesis
|
|
10
|
CBD FOR MULTIPLE SCLEROSIS
|
Sativex for the management of multiple sclerosis symptoms
|
|
CBD FOR MULTIPLE SCLEROSIS
|
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
|
|
CBD FOR MULTIPLE SCLEROSIS
|
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
|
|
CBD FOR MULTIPLE SCLEROSIS
|
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
|
|
CBD FOR MULTIPLE SCLEROSIS
|
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial
|
|
CBD FOR MULTIPLE SCLEROSIS
|
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
|
|
CBD FOR MULTIPLE SCLEROSIS
|
Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis
|
|
CBD FOR MULTIPLE SCLEROSIS
|
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
|
|
CBD FOR MULTIPLE SCLEROSIS
|
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain(
|
|
CBD FOR MULTIPLE SCLEROSIS
|
Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
|
|
6
|
CBD FOR NAUSEA
|
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus
|
|
CBD FOR NAUSEA
|
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation
|
|
CBD FOR NAUSEA
|
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews
|
|
CBD FOR NAUSEA
|
Regulation of nausea and vomiting by cannabinoids
|
|
CBD FOR NAUSEA
|
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats
|
|
CBD FOR NAUSEA
|
Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting
|
|
5
|
CBD FOR NEURODEGENERATION
|
Cannabidiol: A promising drug for neurodegenerative disorders?
|
|
CBD FOR NEURODEGENERATION
|
Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?
|
|
CBD FOR NEURODEGENERATION
|
Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder
|
|
CBD FOR NEURODEGENERATION
|
Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
|
|
CBD FOR NEURODEGENERATION
|
Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection
|
|
18
|
CBD FOR NEUROPATHIC PAIN
|
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
|
|
CBD FOR NEUROPATHIC PAIN
|
Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
|
|
CBD FOR NEUROPATHIC PAIN
|
Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
|
|
CBD FOR NEUROPATHIC PAIN
|
Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial
|
|
CBD FOR NEUROPATHIC PAIN
|
Cannabinoids for neuropathic pain
|
|
CBD FOR NEUROPATHIC PAIN
|
Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
|
|
CBD FOR NEUROPATHIC PAIN
|
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
|
|
CBD FOR NEUROPATHIC PAIN
|
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
|
|
CBD FOR NEUROPATHIC PAIN
|
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
|
|
CBD FOR NEUROPATHIC PAIN
|
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
|
|
CBD FOR NEUROPATHIC PAIN
|
Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: Mechanisms involved
|
|
CBD FOR NEUROPATHIC PAIN
|
Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
|
|
CBD FOR NEUROPATHIC PAIN
|
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
|
|
CBD FOR NEUROPATHIC PAIN
|
Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes
|
|
CBD FOR NEUROPATHIC PAIN
|
Cannabinoids in the management of difficult to treat pain
|
|
CBD FOR NEUROPATHIC PAIN
|
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
|
|
CBD FOR NEUROPATHIC PAIN
|
Marijuana extract helps prevent chemo pain
|
|
CBD FOR NEUROPATHIC PAIN
|
Pot users less likely to take painkillers
|
|
6
|
CBD FOR OBESITY
|
The impact of marijuana use on glucose, insulin, and insulin resistance among US adults
|
|
CBD FOR OBESITY
|
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns
|
|
CBD FOR OBESITY
|
Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?
|
|
CBD FOR OBESITY
|
The endocannabinoid system in obesity and type 2 diabetes
|
|
CBD FOR OBESITY
|
Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk
|
|
CBD FOR OBESITY
|
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes
|
|
3
|
CBD FOR OCD
|
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour (PubMed)
|
|
CBD FOR OCD
|
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour
|
|
CBD FOR OCD
|
Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice
|
|
7
|
CBD FOR PARKINSONS DISEASE
|
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
|
|
CBD FOR PARKINSONS DISEASE
|
Prospects for cannabinoid therapies in basal ganglia disorders
|
|
CBD FOR PARKINSONS DISEASE
|
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent properties
|
|
CBD FOR PARKINSONS DISEASE
|
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease
|
|
CBD FOR PARKINSONS DISEASE
|
Cannabidiol for the treatment of psychosis in Parkinson’s disease
|
|
CBD FOR PARKINSONS DISEASE
|
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease
|
|
CBD FOR PARKINSONS DISEASE
|
Therapeutic potential of cannabinoids in CNS disease
|
|
3
|
CBD FOR PRION
|
Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity
|
|
CBD FOR PRION
|
Cannabidiol: A prion therapy for mice?
|
|
CBD FOR PRION
|
Alteration of the endocannabinoid system in mouse brain during prion disease
|
|
13
|
CBD FOR PTSD
|
The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD
|
|
CBD FOR PTSD
|
Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks
|
|
CBD FOR PTSD
|
Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear
|
|
CBD FOR PTSD
|
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors
|
|
CBD FOR PTSD
|
Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis
|
|
CBD FOR PTSD
|
Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence
|
|
CBD FOR PTSD
|
Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment
|
|
CBD FOR PTSD
|
The endocannabinoid system and extinction learning
|
|
CBD FOR PTSD
|
A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers
|
|
CBD FOR PTSD
|
Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit
|
|
CBD FOR PTSD
|
Non-antidepressant long-term treatment in post-traumatic stress disorder
|
|
CBD FOR PTSD
|
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system
|
|
CBD FOR PTSD
|
Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors
|
|
4
|
CBD FOR RHEUMATISM
|
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
|
|
CBD FOR RHEUMATISM
|
Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases
|
|
CBD FOR RHEUMATISM
|
Clinical Implications for Cannabinoid Use in the Rheumatic Diseases
|
|
CBD FOR RHEUMATISM
|
Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases
|
|
12
|
CBD FOR SCHIZOPHRENIA
|
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
|
|
CBD FOR SCHIZOPHRENIA
|
Cannabidiol as a potential treatment for psychosis
|
|
CBD FOR SCHIZOPHRENIA
|
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
|
|
CBD FOR SCHIZOPHRENIA
|
Medical use of cannabis. Cannabidiol: A new light for schizophrenia?
|
|
CBD FOR SCHIZOPHRENIA
|
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
|
|
CBD FOR SCHIZOPHRENIA
|
Peripheral endocannabinoid system dysregulation in first-episode psychosis
|
|
CBD FOR SCHIZOPHRENIA
|
Cannabinoids and schizophrenia: Therapeutic prospects
|
|
CBD FOR SCHIZOPHRENIA
|
Antipsychotic-like effects of cannabidiol and rimonabant: Systematic review of animal and human studies
|
|
CBD FOR SCHIZOPHRENIA
|
Cannabidiol monotherapy for treatment-resistant schizophrenia
|
|
CBD FOR SCHIZOPHRENIA
|
Cannabis with high cannabidiol content is associated with fewer psychotic experiences
|
|
CBD FOR SCHIZOPHRENIA
|
Marijuana compound treats schizophrenia with few side effects: Clinical trial
|
|
CBD FOR SCHIZOPHRENIA
|
Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?
|
|
3
|
CBD FOR SICKLE CELL ANEMIA
|
Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: Modulation by cannabinoids
|
|
CBD FOR SICKLE CELL ANEMIA
|
Cannabis use in sickle cell disease: A questionnaire study
|
|
CBD FOR SICKLE CELL ANEMIA
|
Cannabinoid Receptor-Specific Mechanisms To Alleviate Pain In Sickle Cell Anemia Via Inhibition Of Mast Cell Activation And Neurogenic Inflammation
|
|
8
|
CBD FOR SKIN CONDITIONS
|
Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis
|
|
CBD FOR SKIN CONDITIONS
|
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
|
|
CBD FOR SKIN CONDITIONS
|
The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities
|
|
CBD FOR SKIN CONDITIONS
|
Epigenetic control of skin differentiation genes by phytocannabinoids
|
|
CBD FOR SKIN CONDITIONS
|
Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1
|
|
CBD FOR SKIN CONDITIONS
|
Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation
|
|
CBD FOR SKIN CONDITIONS
|
Attenuation of allergic contact dermatitis through the endocannabinoid system
|
|
CBD FOR SKIN CONDITIONS
|
Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus
|
|
7
|
CBD FOR SLEEP DISORDERS
|
The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent
|
|
CBD FOR SLEEP DISORDERS
|
Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
|
|
CBD FOR SLEEP DISORDERS
|
Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats
|
|
CBD FOR SLEEP DISORDERS
|
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults
|
|
CBD FOR SLEEP DISORDERS
|
Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats
|
|
CBD FOR SLEEP DISORDERS
|
Endocannabinoid modulation of cortical up-states and NREM sleep
|
|
CBD FOR SLEEP DISORDERS
|
Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat
|
|
4
|
CBD FOR SPINAL CORD INJURY
|
Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury
|
|
CBD FOR SPINAL CORD INJURY
|
Cannabis effect on spasticity in spinal cord injury
|
|
CBD FOR SPINAL CORD INJURY
|
An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease
|
|
CBD FOR SPINAL CORD INJURY
|
Modulation of Inflammatory Responses by a Cannabinoid-2–Selective Agonist after Spinal Cord Injury
|
|
13
|
CBD FOR STRESS
|
Endogenous cannabinoid signaling is essential for stress adaptation
|
|
CBD FOR STRESS
|
Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders
|
|
CBD FOR STRESS
|
Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output
|
|
CBD FOR STRESS
|
Neuromodulators, stress and plasticity: a role for endocannabinoid signalling
|
|
CBD FOR STRESS
|
Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress
|
|
CBD FOR STRESS
|
Endocannabinoids and stress
|
|
CBD FOR STRESS
|
Stress regulates endocannabinoid-CB1 receptor signaling
|
|
CBD FOR STRESS
|
Chronic Stress Impairs α1-Adrenoceptor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus
|
|
CBD FOR STRESS
|
Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance
|
|
CBD FOR STRESS
|
Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression
|
|
CBD FOR STRESS
|
Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory
|
|
CBD FOR STRESS
|
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
|
|
CBD FOR STRESS
|
Low-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid
|
|
6
|
CBD FOR STROKE/TBI
|
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
|
|
CBD FOR STROKE/TBI
|
Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism
|
|
CBD FOR STROKE/TBI
|
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism (
|
|
CBD FOR STROKE/TBI
|
Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function
|
|
CBD FOR STROKE/TBI
|
Protective Effects of Cannabidiol Against Hippocampal Cell Death and Cognitive Impairment Induced by Bilateral Common Carotid Artery Occlusion in Mice
|
|
CBD FOR STROKE/TBI
|
Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance
|
